Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma
- Author
- TONNEL, A. B1 ; BONS, J2 ; LEGENDRE, M; PRUD'HOMME, A4 ; BUGNAS, B; EVANO-CELLI, I2 ; STUART, A. M6
French Study Group, France
[1] Clinique des Maladies Respiratoires, Chru de Lille, Hôpital Calmette, Lille, France
[2] Medical Department, Laboratoire Glaxo Wellcome SA, Marly le Roi, France
[4] Hôpital de la Gespe, Boulevard de Lattre de Tassigny, 65013 Tarbes, France
[6] Respiratory Clinical Development, Glaxo Wellcome, Stockley Park, United Kingdom - Issue title
- Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products
- Source
Respiratory medicine. 2000, Vol 94, pp S29-S34 ; SUPB ; ref : 15 ref
- ISSN
- 0954-6111
- Scientific domain
- Pneumology
- Publisher
- Elsevier, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Asthme Chimiothérapie Corticostéroïde Efficacité traitement Etude comparative Fluticasone Gaz propulseur Homme Inhalateur Toxicité Traitement Antiasthmatique Antiinflammatoire Appareil respiratoire pathologie Bronchopneumopathie obstructive
- Keyword (en)
- Asthma Chemotherapy Corticosteroid Treatment efficiency Comparative study Fluticasone Propellent Human Inhaler Toxicity Treatment Antiasthma agent Antiinflammatory agent Respiratory disease Obstructive pulmonary disease
- Keyword (es)
- Asma Quimioterapia Corticoesteroide Eficacia tratamiento Estudio comparativo Fluticasona Gas propulsor Hombre Inhalador Toxicidad Tratamiento Agente antiasma Antiinflamatorio Aparato respiratorio patología Broncopneumopatía obstructiva
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02D Respiratory system
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1437727
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Respiratory medicine\";s:9:\"\u0000*\u0000stitle\";s:11:\"Respir. med\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"S29\";s:8:\"\u0000*\u0000epage\";s:3:\"S34\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0954-6111\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"TONNEL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:7:\"BONS, J\";i:1;s:11:\"LEGENDRE, M\";i:2;s:13:\"PRUD'HOMME, A\";i:3;s:9:\"BUGNAS, B\";i:4;s:14:\"EVANO-CELLI, I\";i:5;s:12:\"STUART, A. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUPB\";s:9:\"\u0000*\u0000btitle\";s:105:\"Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products\";s:8:\"\u0000*\u0000title\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Respiratory medicine\";s:9:\"\u0000*\u0000stitle\";s:11:\"Respir. med\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"S29\";s:8:\"\u0000*\u0000epage\";s:3:\"S34\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0954-6111\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"TONNEL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:7:\"BONS, J\";i:1;s:11:\"LEGENDRE, M\";i:2;s:13:\"PRUD'HOMME, A\";i:3;s:9:\"BUGNAS, B\";i:4;s:14:\"EVANO-CELLI, I\";i:5;s:12:\"STUART, A. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUPB\";s:9:\"\u0000*\u0000btitle\";s:105:\"Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products\";s:8:\"\u0000*\u0000title\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Respiratory medicine\";s:9:\"\u0000*\u0000stitle\";s:11:\"Respir. med\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"S29\";s:8:\"\u0000*\u0000epage\";s:3:\"S34\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0954-6111\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"TONNEL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:7:\"BONS, J\";i:1;s:11:\"LEGENDRE, M\";i:2;s:13:\"PRUD'HOMME, A\";i:3;s:9:\"BUGNAS, B\";i:4;s:14:\"EVANO-CELLI, I\";i:5;s:12:\"STUART, A. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUPB\";s:9:\"\u0000*\u0000btitle\";s:105:\"Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products\";s:8:\"\u0000*\u0000title\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Respiratory medicine\";s:9:\"\u0000*\u0000stitle\";s:11:\"Respir. med\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"S29\";s:8:\"\u0000*\u0000epage\";s:3:\"S34\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0954-6111\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"TONNEL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:7:\"BONS, J\";i:1;s:11:\"LEGENDRE, M\";i:2;s:13:\"PRUD'HOMME, A\";i:3;s:9:\"BUGNAS, B\";i:4;s:14:\"EVANO-CELLI, I\";i:5;s:12:\"STUART, A. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUPB\";s:9:\"\u0000*\u0000btitle\";s:105:\"Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products\";s:8:\"\u0000*\u0000title\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:9:\"\u0000*\u0000jtitle\";s:20:\"Respiratory medicine\";s:9:\"\u0000*\u0000stitle\";s:11:\"Respir. med\";s:7:\"\u0000*\u0000date\";s:4:\"2000\";s:9:\"\u0000*\u0000volume\";s:2:\"94\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"S29\";s:8:\"\u0000*\u0000epage\";s:3:\"S34\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0954-6111\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"TONNEL\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. B\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:7:\"BONS, J\";i:1;s:11:\"LEGENDRE, M\";i:2;s:13:\"PRUD'HOMME, A\";i:3;s:9:\"BUGNAS, B\";i:4;s:14:\"EVANO-CELLI, I\";i:5;s:12:\"STUART, A. M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUPB\";s:9:\"\u0000*\u0000btitle\";s:105:\"Ventolin and flixotide: a pharmaceutical, pharmacological and clinical comparison of HFA and CFC products\";s:8:\"\u0000*\u0000title\";s:176:\"Clinical efficacy and safety of fluticasone propionate 250 \u03bcg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
